All 1 tracked stories fall under one category: market-trends. BF-RhodoLED is most often covered alongside Ameluz, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about BF-RhodoLED
All 1 tracked stories fall under one category: market-trends. BF-RhodoLED is most often covered alongside Ameluz, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. BF-RhodoLED appears in 1 tracked Healthcare story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering BF-RhodoLED. Shared-story counts are live from our verified record — not editorial picks.
Biofrontera Inc. (Nasdaq: BFRI) has reported record-breaking financial results for the fourth quarter and full year 2025, signaling a major milestone in the commercial adoption of its photodynamic therapy (PDT) solutions. The company is leveraging increased market penetration of its flagship product, Ameluz, and its proprietary BF-RhodoLED lamps across U.S. dermatology practices.
